cardiovascular outcomes glp-1 news today Risks after Discontinuation 363. GLP-1 Agonists: Diving into

A new study shows the medications could have a broader effect on addiction.

A component of the Gila monsters venoma peptide known as exendin-4is being explored for new treatments for Alzheimers disease, diabetes, and other diseases.

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Hansoh Pharma, a Chinese biopharmaceutical company, today announced that they have entered into an exclusive global license agreement for HS-10535, an investigational preclinical oral small molecule GLP-1 receptor agonist

Using a global dataset and propensity matching, they found significantly lower mortality rates, major cardiovascular events (MACEs), and adverse kidney outcomes (MAKEs) among GLP-1 RA users compared to non-users

Coronary artery disease (CAD)cardiovascular condition occuring due to atherosclerotic plaque accumulation in the epicardial arteriesis responsible for disa...

These medications are commonly administered through prefilled syringes or injection p...